OpGen OPGN shares are trading higher after the company announced its subsidiary obtained the CE mark certification in the European Union for its own SARS-CoV-2 Kit with PULB detection of SARS-CoV-2.
"The CE-IVD Marking is an important step in advancing our efforts to support critical COVID-19 testing; the Curetis SARS-CoV-2 Kit with PULB provides additional testing capacity in countries that recognize the CE Mark to test patients," said Johannes Bacher, COO of OpGen.
OpGen is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease.
OpGen was trading 48.24% higher at $3.04 at time of publication on Thursday. The stock has a 52-week high of $12.8 and a 52-week low of $0.92.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
